Скачать с ютуб Spain, convincing therapeutic evidence в хорошем качестве

Spain, convincing therapeutic evidence

Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study (October 2020) https://www.ncbi.nlm.nih.gov/pmc/arti... n = 76, Calcifediol treatment 50 patients treated with calcifediol One required admission to ICU (2%) No deaths 26 untreated patients 13 required admission to ICU (50 %) 2 deaths Calcifediol treatment and COVID-19-related outcomes (22nd January) Barna-COVIDIOL Barcelona https://papers.ssrn.com/sol3/papers.c... Effect of calcifediol treatment In admitted patients On ICU admission and mortality N = 930 Randomly assigned Calcifediol treatment group n = 551 Day one, 532 ug (21,000 iu) Days, 3, 7, 15, 30, 266 ug (10,640 iu) No adverse effects reported Required ICU, 30 (5.4%) Deaths, 36 (6.5%) Death RR = 0.36 64% reduced chance of death Control group n = 379 Required ICU, 80 (21.1%), p less than 0.0001 Deaths, 57 (15%), p = 0.001 Adjusted for Age Sex Comorbidities Linearized 25(OH)D levels at baseline Treated patients Reduced risk to require ICU RR 0.18 Baseline 25(OH)D levels Inversely correlated with the risk of ICU Predictors of reduced mortality Higher baseline 25(OH)D levels Predictors on increased mortality Age Obesity Interpretation In patients hospitalized with COVID-19, calcifediol treatment at the time of hospitalization significantly reduced ICU admission and mortality. Early calcifediol after admission Prior to ARDS development, is critical for mortality reduction Initiation of calcifediol during ICU admission did not modify patient survival